| 查看: 1810 | 回复: 101 | |||
[交流]
【转自药渡网】Teva 报告了乐观哮喘临床3期评估结果
|
|||
|
Teva 对临床3期评估了对于哮喘患者干粉吸入器 (MDPIs)吸入Fluticasone Propionate /Salmeterol和多剂量Fluticasone Propionate 的实验效果，实验数据很好。研究表明通过使用干粉吸入器 (MDPI)，低剂量与安慰剂相比具有更大的效能，结果展示 Teva 扩大呼吸的研发能力和支持其核心，呼吸驱动MDPI平台的发展。最初的结果显示fluticasone propionate/salmeterol MDPI的不良事件可以和fluticasone propionate治疗和安慰剂媲美。 相关阅读： Teva Reports Positive Top-Line Results from Phase III Trials Evaluating Fluticasone Propionate/Salmeterol and Fluticasone Propionate Multidose Dry Powder Inhalers (MDPIs) in Patients with Asthma Studies demonstrate greater efficacy with lower doses delivered via multidose dry-powder inhaler (MDPI) compared to placebo Results showcase Teva’s expanding respiratory R&D capabilities and support advancement of core, breath-actuated MDPI platform Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced positive top-line results from three Phase III clinical studies designed to evaluate the efficacy and safety of fluticasone propionate/salmeterol, a combination inhaled corticosteroid (ICS) and long-acting beta agonist (LABA) delivered via a multidose dry powder inhaler (MDPI) and fluticasone propionate, an ICS monotherapy delivered via a MDPI in adolescent and adult patients with asthma. Top-line data showed that the studies met their primary endpoints. Importantly, the studies also showed similar overall safety profiles as compared to therapies in the corresponding drug classes. “These data support Teva’s commitment to further optimize the treatment of respiratory disease through the development of devices and therapies that help address the needs of patients and physicians,” said Tushar Shah, MD, Senior Vice President, Teva Global Respiratory Research and Development. “With this dual development program we have demonstrated clinically significant levels of effectiveness, by delivering combination and monotherapy at lower doses utilizing our core, breath-actuated, MDPI platform.” Fluticasone propionate/salmeterol MDPI demonstrated, in the double-blind studies, clinically relevant and greater benefit at all doses (50/12.5, 100/12.5, and 200/12.5 mcg BID nominal delivered doses) versus placebo and versus respective monotherapy (fluticasone propionate) in the improvement of lung function as measured by the change from baseline in trough Forced Expiratory Volume in one second (FEV1) at the 12-week trial period and standardized baseline-adjusted area under the effect curve FEV1 from time 0 to 12 hours post dose at Week 12. This initial set of results shows the adverse event profile of fluticasone propionate/salmeterol MDPI was comparable to fluticasone propionate monotherapy and placebo. Fluticasone propionate MDPI also demonstrated clinically relevant and greater benefit at all doses (50, 100, and 200 mcg BID nominal delivered doses) versus placebo in the improvement of lung function, in the double-blind studies. The initial set of results shows the adverse event profile of fluticasone propionate MDPI was comparable to placebo. The majority of adverse events were mild to moderate in severity. There were no drug-related deaths across any of the trials. Further analyses of additional efficacy and safety data are ongoing. Full results will be submitted for presentation at future scientific meetings and for publication in peer reviewed journals. “We have made significant progress in furthering our respiratory pipeline with a focus on a complete asthma management system utilizing our breath-actuated MDPI platform,” said Michael Hayden, M.D., Ph.D., President of Global R&D and Chief Scientific Officer at Teva. “We have successfully developed and launched products that utilize our breath-actuated MDPI platform in select markets around the world. These data support the broadening of our portfolio in using this technology to develop and deliver additional respiratory therapeutic options.” Regulatory submissions for both fluticasone propionate/salmeterol MDPI and fluticasone propionate MDPI in the U.S. are planned for 2016. |
回复此楼» 猜你喜欢
求调剂
已经有4人回复
-
0854求调剂
已经有27人回复
-
材料相关专业344求调剂双非工科学校或课题组
已经有27人回复
-
300求调剂
已经有12人回复
-
291求调剂
已经有10人回复
-
一志愿沪9，326求生物学调剂
已经有12人回复
-
生物学调剂
已经有10人回复
-
320求调剂
已经有5人回复
-
接受任何调剂
已经有7人回复
-
化学070300 求调剂
已经有29人回复
» 抢金币啦！回帖就可以得到:
-
广东石油化工学院环境工程专业硕士生，大类07，08，09都可以调剂，先到先得！
+1/485
-
坐标山东，诚征女友
+1/347
-
封闭系统的熵守恒悖论
+1/192
-
欧洲“CO2捕集与加氢催化转化”博士招聘（捷克-德国-斯洛文尼亚三国项目）
+1/89
-
广西师范大学化学工程与技术专业2026年硕士研究生招生开通第二次调剂，系统12:00关闭
+1/83
-
江西科技师范大学086生物与医药
+1/37
-
江西科技师范大学086生物与医药
+1/36
-
成都大学药学院-药学1055专硕：新导师开山弟子火热招募中
+1/33
-
郑州大学物理学院倪佩楠教授课题组诚邀博士后、青年教师及副教授加盟
+1/33
-
上海交通大学-电气工程学院-高温超导磁体-2026年入学全日制博士生招聘
+1/32
-
北京航空航天大学-仿生界面材料科学全国重点实验室 康建新 教授招收博士一名
+2/30
-
中科院2区Top期刊IJBM（IF=8.5）征稿-截止到4月底
+2/30
-
瑞典 Linköping University 诚聘 氮化物基无机材料方向 博士后1名
+1/26
-
吉林大学李凯伟课题组招光纤传感器、触觉传感器方向博士生
+1/11
-
C13、N15标记植物，助力土壤碳氮循环与地学研究实操
+1/8
-
青岛科技大学高分子学院硕士招生
+1/7
-
山东大学集成电路学院招博士了
+1/5
-
山东大学集成电路学院招博士了
+1/4
-
大连海洋大学资源与环境专硕（0857）接收调剂学生
+1/1
-
知名外资仪器厂家急招Application Scientist-成都上海
+1/1
★
药渡(金币+1): 谢谢参与
药渡(金币+1): 谢谢参与
|
本帖内容被屏蔽 |
14楼2015-11-20 16:01:12
简单回复
sxln2楼
2015-11-20 15:48
回复
药渡(金币+1): 谢谢参与
laom20133楼
2015-11-20 15:50
回复
药渡(金币+1): 谢谢参与
2015-11-20 15:50
回复
药渡(金币+1): 谢谢参与
2015-11-20 15:50
回复
药渡(金币+1): 谢谢参与
。 发自小木虫Android客户端
天涯20126楼
2015-11-20 15:51
回复
药渡(金币+1): 谢谢参与
skyish7楼
2015-11-20 15:52
回复
药渡(金币+1): 谢谢参与
2015-11-20 15:54
回复
药渡(金币+1): 谢谢参与
dmbb9楼
2015-11-20 15:57
回复
药渡(金币+1): 谢谢参与
江南的竹10楼
2015-11-20 15:58
回复
药渡(金币+1): 谢谢参与
。 [ 发自小木虫客户端 ]
chenchenyf11楼
2015-11-20 15:59
回复
药渡(金币+1): 谢谢参与
xiejiaf12楼
2015-11-20 16:00
回复
药渡(金币+1): 谢谢参与
feiyief13楼
2015-11-20 16:01
回复
药渡(金币+1): 谢谢参与
mhycpxir15楼
2015-11-20 16:01
回复
药渡(金币+1): 谢谢参与
irshvj16楼
2015-11-20 16:02
回复
药渡(金币+1): 谢谢参与
kolimm17楼
2015-11-20 16:02
回复
药渡(金币+1): 谢谢参与
祝福
am435918楼
2015-11-20 16:02
回复
药渡(金币+1): 谢谢参与
wblxcs19楼
2015-11-20 16:02
回复
药渡(金币+1): 谢谢参与
祝福
wnotffisg20楼
2015-11-20 16:03
回复
药渡(金币+1): 谢谢参与
祝福
ahsjlyu21楼
2015-11-20 16:03
回复
药渡(金币+1): 谢谢参与
.
keoxri22楼
2015-11-20 16:03
回复
药渡(金币+1): 谢谢参与
vrxcyvkss23楼
2015-11-20 16:03
回复
药渡(金币+1): 谢谢参与
,
ooxmfc24楼
2015-11-20 16:04
回复
药渡(金币+1): 谢谢参与
ucmxjl25楼
2015-11-20 16:04
回复
药渡(金币+1): 谢谢参与
,
bincmq26楼
2015-11-20 16:04
回复
药渡(金币+1): 谢谢参与
祝福
fqmkia27楼
2015-11-20 16:04
回复
药渡(金币+1): 谢谢参与
wxubpn28楼
2015-11-20 16:05
回复
药渡(金币+1): 谢谢参与
祝福
iygbojqj29楼
2015-11-20 16:05
回复
药渡(金币+1): 谢谢参与
sjtdeud30楼
2015-11-20 16:05
回复
药渡(金币+1): 谢谢参与
shsvoy31楼
2015-11-20 16:05
回复
药渡(金币+1): 谢谢参与
cmyfna32楼
2015-11-20 16:06
回复
药渡(金币+1): 谢谢参与
sgadsdkc33楼
2015-11-20 16:06
回复
药渡(金币+1): 谢谢参与
,
quainyni34楼
2015-11-20 16:06
回复
药渡(金币+1): 谢谢参与
wbwwrs35楼
2015-11-20 16:06
回复
药渡(金币+1): 谢谢参与
祝福
yuduoj36楼
2015-11-20 16:06
回复
药渡(金币+1): 谢谢参与
支持
ofresq37楼
2015-11-20 16:06
回复
药渡(金币+1): 谢谢参与
.
tanmingp38楼
2015-11-20 16:06
回复
药渡(金币+1): 谢谢参与
qdjoupudwqx39楼
2015-11-20 16:06
回复
药渡(金币+1): 谢谢参与
,
qyoycw40楼
2015-11-20 16:07
回复
药渡(金币+1): 谢谢参与
fangfengw41楼
2015-11-20 16:07
回复
药渡(金币+1): 谢谢参与
祝福
virologik42楼
2015-11-20 16:07
回复
药渡(金币+1): 谢谢参与
liufeic43楼
2015-11-20 16:07
回复
药渡(金币+1): 谢谢参与
xiachaz44楼
2015-11-20 16:07
回复
药渡(金币+1): 谢谢参与
hodydo45楼
2015-11-20 16:07
回复
药渡(金币+1): 谢谢参与
zhangfangp46楼
2015-11-20 16:07
回复
药渡(金币+1): 谢谢参与
hudouz47楼
2015-11-20 16:07
回复
药渡(金币+1): 谢谢参与
祝福
ffwmeg48楼
2015-11-20 16:07
回复
药渡(金币+1): 谢谢参与
.
yushat49楼
2015-11-20 16:07
回复
药渡(金币+1): 谢谢参与
qiyingy50楼
2015-11-20 16:07
回复
药渡(金币+1): 谢谢参与
支持
